DOCSLIB.ORG

Northeast Ohio Medical University

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Northeast Ohio Medical University NORTHEAST OHIO MEDICAL UNIVERSITY DEPARTMENT OF ANATOMY & NEUROBIOLOGY Presents Synapses, muscular dystrophy and schizophrenia By Lin Mei, Ph.D. Chairman & Professor Department of Neurosciences School of Medicine Case Western Reserve University Director Cleveland Brain Health Initiative Thursday, January 10, 2019 4:00 p.m. F-118 For further information, please call (330) 325-6293 or (330) 325-6636 Page 1 of 37 Lin Mei Curriculum Vitae Department of Neurosciences School of Medicine Case Western Reserve University 10900 Euclid Ave. Cleveland, OH 44106-4975 Office Phone: 216-368-4928 Email: [email protected] Education: Diploma of Medicine, 1982, Jiangxi Medical College, Nanchang, China M.S. (Neuropharmacology), 1985, Institute of Pharmacology & Toxicology, Beijing, China. Advisor: Professor Jin-Chu Yan PhD (Pharmacology and Toxicology), 1989, University of Arizona, Tucson, Arizona. Advisors: Professors Henry I. Yamamura and William Roeske Appointments: 1981-1982, Intern, First Affiliated Hospital, Jiangxi Medical College, Nanchang, China 1989-1994, Postdoctoral Fellow/Research Associate, HHMI, Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, Maryland. Advisor: Professor Richard Huganir 1994-1999, Assistant Professor, Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, Virginia 1999-2002, Assistant Professor, Neurobiology, Pathology, and Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama 2002-2004, Associate Professor, Neurobiology, Pathology, and Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama 2004-2017, Professor, Department of Neurology, School of Medicine, Augusta University (formerly Medical College of Georgia, Georgia Health Sciences University, and Georgia Regents University), Augusta, Georgia 2004-2017, Georgia Research Alliance Eminent Scholar in Neuroscience 2004-2009, Chief, Program of Developmental Neurobiology, Institute of Molecular Medicine and Genetics, Augusta University, Augusta, Georgia 2009-3/2014, Director, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta University, Augusta, Georgia 4/2014-10/2017, Professor and Chair (Inaugural), Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia 11/2017-Present, Professor and Chair, Department of Neuroscience, Case Western Reserve University School of Medicine, Cleveland, Ohio 11/2017-Present, Allen C. Holmes Professor of Neurological Diseases, Case Western Reserve University, Cleveland, Ohio 11/2017-Present, Director, Cleveland Brain Health Initiative Professional Experience: 1996 – 2010, Guest Investigator, the Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, China - 1 - 1999 – 2008, Member, Council of the Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, China 2003, Monitor, Neural Plasticity, Gordon Research Conference 2006 – 2015, Visiting Professor, Southern Medical University, Guangzhou, China 2008 – 2015, Member, Eminent Scholar Advisory Group, Georgia Research Alliance 2009, 2013, Ad Hoc Member, Board of Scientific Councilors, NIMH, NIH 2011, Member, Chancellor Search Committee, Board of Regents, University System of Georgia 2011 – 2012, Member, Scientific Advisory Board, Mind-NRG, Switzerland 2013, Member, Board of Trustees, Georgia Research Alliance 2013 – Present, Member, International Advisory Board, International Symposium on Cholinergic Mechanisms (ISCM) 2013 – Present, Visiting Professor, Nanchang University, Nanchang, Jiangxi, China Professional Societies: Alpha Psi Chapter of Rho Chi Honor Society, since 1987 Society for Neuroscience, since 1994; Membership and Chapters Committee, 2007-2010; Achievement Awards Selection Committee, 2010 – 2012 Chinese Biological Investigators Society (CBIS), since 1998, Treasurer, 2006 – 2010 Society of Chinese Bioscientists in America (SCBA), since 1994; Council member, 2015- 2017 American Association for the Advancement of Science (AAAS), since 2000; Fellow, since 2013 American College of Neuropsychopharmacology (ACNP), since 2012; Program Committee (2015 - present) 2018 - 2022 Member, Committee on Committee, Society for Neuroscience Grant Review Service: Chartered Members of NIH Study Sections: 2003 – 2005, Chartered Member, NIH Syn (Synapses, Cytoskeleton and Trafficking) Study Section 2007 – 2011, Chartered Member and Ad Hoc Chair, NIH CHHD-C (2) (Child Health and Human Development) Study Section 2011 – 2013, Chartered Member, NIH PMDA (Pathophysiological Basis of Mental Disorders and Additions) Study Section 2018 – 2023, Chartered Member, NIH NDPR (Neurodifferentiation, Plasticity, and Regeneration) Study Section Ad Hoc Members of NIH Study Sections: 2000 – 2003, NIH MCDN-1 Study Section 2004, Reviewer of Cutting Edge Basic Research Award Program (CEBRA, NIDA), NIH 2005, NIH MDCN-F (04) Study Section 2006, NIH ZRG1 NDBG-A Study Section & CHHD-C Study Section 2007, NIH CEBRA ZDA1 MXS-M (01) Study Section 2007, 2008, 2010, 2011, Ad Hoc Reviewer, NIH NDPR Study Section 2010, NIH ZRG1 MDCN-G (91) S Study Section 2011, NIH ZRG1 MDCN-F (04) Study Section 2011, NIH ZHD1 DSR-Y (50) Study Section 2011, NIH Special Emphasis Panel ZRG1 MDCN-P (57) 2012 NIH Special Emphasis Panel ZRG1 MDCN-P (57) 2013, NIH ZRG1 BDCN-C (02) Study Section - 2 - Page 3 of 37 2013, NIH ZRG1 F03B-G (20) L Study Section 2014, NIH PMDA Study Section 2014, NIH Clinical Neuroplasticity and Neurotransmitters (CNNT) Study Section 2014, NIH ZRG1 BDCN-C (02) M (Developmental Brain Disorder and Psychiatric Disorders) 2014, NIH ZMH1 ERB-L (01) P (Conte Centers for Basic or Translational Mental Health Research, P50) 2015, Chair, NIH ZRG1 BDCN-L (03) M (Brain Disorders & Clinical Neuroscience) 2015, NIH PMDA Study Section 2015, 2016, NIH MDCN-R (86) R15 AREA Study Section 2016, NIH New Innovator Award Review 2016, VA RRD Career Development Award Program 2016, NIH ZRG1 MDCN-A (02) 2016, NIH Molecular and Cellular Substrates of Complex Brain Disorders Special Emphasis Panel ZRG1 MDCN-P (57) 2016, NIH ZRG1 MDCN-R (86) Academic Research Enhancement Award (AREA) 2017, NIH ZRG1 MDCN-R (86) Academic Research Enhancement Award (AREA) 2017, NDPR (Neurodifferentiation, Plasticity, and Regeneration Study Section) 2017, NIH Neurodevelopment, Synaptic Plasticity, and Neurodegeneration panel (F03A) 2018, Co-Chair, ZRG1 BDCN-W(05) (Brain Disorders and Clinical Neuroscience), NIH. 2018, Simons Foundation Autism Research Initiative (SFARI), SIMONS FOUNDATION Reviewer for other funding agencies: 2003 – 2005, Member, Oversea Review Board, National Natural Science Foundation, China Ad Hoc Grant Review Activities for Department of Veterans Affairs (since 1996), Natural Sciences and Engineering Research Council of Canada (1998), National Science Foundation (since 1998), Jewish Hospital Foundation (1999), Bank of America (2000), Raine Medical Research Foundation, Australia (2000), Philip Morris External Research Program (2001-2005), Muscular Dystrophy Association (since 2003), Italian Telethon Review (since 2003), Czech Science Foundation (2004), Alzheimer’s Disease Association (since 2004), Austrian Science Fund (2004), North Carolina Biotechnology Center (2004), Research Grant Council, Hong Kong (since 2005), Oak Ridge Associated Universities (since 2005), Swiss Science Foundation (2007), Welcome Trust (since 2008), Association Française contre les Myopathies (since 2010), Fund for Scientific Research (Belgium) (since 2011), Council for the Earth and Life Sciences (the Netherlands), French National Research Agency (2015), Medical Research Council (MRC), UK. Editorial Service: 2000 – Present, Member, Editorial Board, NeuroSignals 2005 – Present, Member, Editorial Board, Neuroscience Bulletin 2007 – Present, Academic Editor, PLoS ONE 2007 – 2010, Member, Editorial Board, Brain Research Bulletin 2008 – 2010, Editor-in-Chief, 2010 – present, Section Editor, Molecular Brain 2010 – 2016, Associate Editor, Journal of Neuroscience 2014 – Present, Associate Editor, Cell & Bioscience 2014 – Present, Member, Editorial Board, Neurology: Neuroimmunology and Neuroinflammation 2015 – Present, Member, Editorial Board, Scientific Reports 2017-present, Member, Editorial Board, Brain Research - 3 - Ad Hoc Reviewer for more than 50 journals including American Journal of Physiology, American Journal of Psychiatry, Biological Psychiatry, Brain Research, Cell Reports, Current Biology, Developmental Biology, Development, Developmental Cell, Developmental Neurobiology, eLife, EMBO Journal, European Journal of Neuroscience, EMBO Journal, FASEB Journal, Human Molecular Genetics, Journal of Biological Chemistry, Journal of Cell Biology, Journal of Clinical Investigation, Journal of Cell Science, Journal of Comparative Neurology, Journal of Neuroscience, Journal of Physiology, Molecular Biology of Cell, Molecular Cell, Molecular Cellular Biology, Molecular Cellular Neuroscience, Molecular Psychiatry, Nature, Nature Communications, Nature Methods, Nature Neuroscience, Nature Review Neuroscience, Neuron, Neuropsychopharmacology, Neuroscience, Oncogene, Physiological Review, PLoS Biology, Proceedings of National Academy of Sciences, Science, Translational Psychiatry, and Trends in Neuroscience. Meeting Organization Service: 2004, Co-Chair, Symposium for Chinese Neuroscientists Worldwide 2004, Guangzhou, China 2009, Co-Chair, Program Committee of 2009 International Symposium, Society of Chinese Bioscientists in America
Load more

Recommended publications
  • Vaccines Currently in Development
    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES Begin Phase 1 trials in late TAK-888, antibodies from PhRMA spring. To patients between 1 recovered COVID-19 N/A Takeda Pre-clinical Wall Street Journal December 2020 and December patients Pink Sheet 2021 Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Antibodies from recovered Korea Herald 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 COVID-19 patients UPI Antibodies from recovered BioSpace 4 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 5 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech Antibodies from recovered Lilly/Ab-Cellera (NIH Vaccines 6 N/A Pre-clinical Start Phase 1 in late July 2020 Endpoints News COVID-19 patients Research Center) * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources. It is not an endorsement Copyright 2020 Updated April 2, 2020, at 2:30 p.m.
    [Show full text]
  • A Mirna-Based Signature Predicts Development of Disease Recurrence in HER2 Positive Breast Cancer After Adjuvant Trastuzumab- Based Treatment F
    www.nature.com/scientificreports OPEN Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab- based treatment F. Du, P. Yuan, Z. T. Zhao, Z. Yang, T. Wang, J. D. Zhao, Y. Luo, F. Ma, J. Y. Wang, Y. Fan, R. G. Cai, P. Zhang, Q. Li, Y. M. Song & B. H. Xu Scientific Reports 6:33825; doi: 10.1038/srep33825; published online 21 September 2016; updated on 14 October 2016 The Acknowledgements section in the PDF version of this Article is incorrect. “The following institutions participated in this study: Fudan University Shanghai Cancer Center; Zhejiang Cancer Hospital; Guangdong General Hospital; Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology; Nanfang Hospital, Southern Medical University; Sun Yat-Sen University Cancer Hospital; West China Hospital, Sichuan University; Harbin Medical University Cancer Hospital; Henan Cancer Hospital, Zhengzhou University; Peking Union Medical College Hospital. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI14C0466), and funded by the Ministry of Health & Welfare, Republic of Korea (HI14C3344)”. should read: “The following institutions participated in this study: Fudan University Shanghai Cancer Center; Zhejiang Cancer Hospital; Guangdong General Hospital; Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology; Nanfang Hospital, Southern Medical University; Sun Yat-Sen University Cancer Hospital; West China Hospital, Sichuan University; Harbin Medical University Cancer Hospital; Henan Cancer Hospital, Zhengzhou University; Peking Union Medical College Hospital. This work was supported by Beijing Hope Run Special Fund (LC2013L09) and Capital Clinical Feature Applied Research Fund (Z141107002514010).
    [Show full text]
  • De Draagbare Wikipedia Van Het Schrijven – Verhaal
    DE DRAAGBARE WIKIPEDIA VAN HET SCHRIJVEN VERHAAL BRON: WIKIPEDIA SAMENGESTELD DOOR PETER KAPTEIN 1 Gebruik, verspreiding en verantwoording: Dit boek mag zonder kosten of restricties: Naar eigen inzicht en via alle mogelijke middelen gekopieerd en verspreid worden naar iedereen die daar belangstelling in heeft Gebruikt worden als materiaal voor workshops en lessen Uitgeprint worden op papier Dit boek (en het materiaal in dit boek) is gratis door mij (de samensteller) ter beschikking gesteld voor jou (de lezer en gebruiker) en niet bestemd voor verkoop door derden. Licentie: Creative Commons Naamsvermelding / Gelijk Delen. De meeste bronnen van de gebruikte tekst zijn artikelen van Wikipedia, met uitzondering van de inleiding, het hoofdstuk Redigeren en Keuze van vertelstem. Deze informatie kon niet op Wikipedia gevonden worden en is van eigen hand. Engels In een aantal gevallen is de Nederlandse tekst te kort of non-specifiek en heb ik gekozen voor de Engelse variant. Mag dat zomaar met Wikipedia artikelen? Ja. WikiPedia gebruikt de Creative Commons Naamsvermelding / Gelijk Delen. Dit houdt in dat het is toegestaan om: Het werk te delen Het werk te bewerken Onder de volgende voorwaarden: Naamsvermelding (in dit geval: Wikipedia) Gelijk Delen (verspreid onder dezelfde licentie als Wikipedia) Link naar de licentie: http://creativecommons.org/licenses/by-sa/3.0/deed.nl Versie: Mei 2014, Peter Kaptein 2 INHOUDSOPGAVE INLEIDING 12 KRITIEK EN VERHAALANALYSE 16 Literaire stromingen 17 Romantiek 19 Classicisme 21 Realisme 24 Naturalisme 25
    [Show full text]
  • Curriculum Vitae Huiyun Xiang, M.D
    Curriculum Vitae Huiyun Xiang, M.D., M.P.H., Ph.D. Professional Address Home Address Center for Injury Research and Policy 4506 Bradford Road The Research Institute at Nationwide Children’s Hospital Upper Arlington, OH 43220 700 Children’s Drive Phone: (614) 459-8248 Columbus, OH 43205 Phone: (614) 355-2768 Fax: (614) 722-2448 Email: [email protected] Academic Education 1999 Ph.D. College of Veterinary Medicine and Biomedical Sciences Colorado State University Major: Injury Epidemiology 1991 M.P.H. School of Public Health Tongji Medical College Major: Health Statistics 1988 M.D. Tongji Medical College Major: Preventive Medicine Special Training 2006-2007 Upper Arlington Leadership Program City of Upper Arlington, Columbus, Ohio 2001-2002 Advanced Public Health Leadership Fellow Regional Institute for Health & Environmental Leadership Denver University 2000 Colorado Advanced Supervisory Leadership Training Colorado State Department of Personnel and Administration 1999 Colorado Supervisory Leadership Training Colorado State Department of Personnel and Administration Professional Employment Huiyun Xiang, MD MPH PhD - 2 - 2009-Present Associate Professor Associate Director of Professional Development Center for Injury Research and Policy The Research Institute at Nationwide Children’s Hospital Department of Pediatrics College of Medicine The Ohio State University 2003- 2008 Assistant Professor Associate Director of Professional Development Center for Injury Research and Policy The Research Institute at Nationwide Children’s
    [Show full text]
  • (TJDBPS01): Study Protocol for a Multicenter Randomized Controlled Trial
    Total laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy (TJDBPS01): study protocol for a multicenter randomized controlled trial. Hang Zhang1, Junfang Zhao1, Yechen Feng1, Rufu Chen2, Xuemin Chen3, Wei Cheng4, Dewei Li5, Jingdong Li6, Xiaobing Huang7, Heguang Huang13, Deyu Li14, Jing Li7, Jianhua Liu8, Jun Liu9, Yahui Liu10, Zhijian Tan11, Xinmin Yin4, Wenxing Zhao12, Yahong Yu1, Min Wang1✉, Renyi Qin1 ✉. Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China’s International Exchange and Promotion Association for Medicine and Healthcare. 1 Department of Biliary–Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. 2 Department of Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 3 Department of Pancreaticobiliary Surgery, The Third Affiliated Hospital of Soochow University, Jiangsu 213000, China. 4 Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410000, China. 5 Department of Hepatobiliary Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing 404100, China. 6 Department of Pancreatico-Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China. 7 Department of Pancreatico-Hepatobiliary Surgery, The Second Affiliated Hospital, Army Medical University, PLA, Chongqing 404100, China. 8 Department of Hepato–Pancreato–Biliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, China. 9 Department of Hepato–Pancreato–Biliary Surgery, Shandong Provincial Hospital, Shandong 250000, China. 10 Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, China. 11 Department of Hepatobiliary and Pancreatic Surgery, Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China.
    [Show full text]
  • A Visualization Quality Evaluation Method for Multiple Sequence Alignments
    2011 5th International Conference on Bioinformatics and Biomedical Engineering (iCBBE 2011) Wuhan, China 10 - 12 May 2011 Pages 1 - 867 IEEE Catalog Number: CFP1129C-PRT ISBN: 978-1-4244-5088-6 1/7 TABLE OF CONTENTS ALGORITHMS, MODELS, SOFTWARE AND TOOLS IN BIOINFORMATICS: A Visualization Quality Evaluation Method for Multiple Sequence Alignments ............................................................1 Hongbin Lee, Bo Wang, Xiaoming Wu, Yonggang Liu, Wei Gao, Huili Li, Xu Wang, Feng He A New Promoter Recognition Method Based On Features Optimal Selection.................................................................5 Lan Tao, Huakui Chen, Yanmeng Xu, Zexuan Zhu A Center Closeness Algorithm For The Analyses Of Gene Expression Data ...................................................................9 Huakun Wang, Lixin Feng, Zhou Ying, Zhang Xu, Zhenzhen Wang A Novel Method For Lysine Acetylation Sites Prediction ................................................................................................ 11 Yongchun Gao, Wei Chen Weighted Maximum Margin Criterion Method: Application To Proteomic Peptide Profile ....................................... 15 Xiao Li Yang, Qiong He, Si Ya Yang, Li Liu Ectopic Expression Of Tim-3 Induces Tumor-Specific Antitumor Immunity................................................................ 19 Osama A. O. Elhag, Xiaojing Hu, Weiying Zhang, Li Xiong, Yongze Yuan, Lingfeng Deng, Deli Liu, Yingle Liu, Hui Geng Small-World Network Properties Of Protein Complexes: Node Centrality And Community Structure
    [Show full text]
  • A Collaborative Online AI Engine for CT-Based COVID-19 Diagnosis
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.10.20096073; this version posted May 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . 1 A collaborative online AI engine for CT-based COVID-19 diagnosis 2 3 Yongchao Xu1,2#, Liya Ma1#, Fan Yang3#, Yanyan Chen4#, Ke Ma2, Jiehua Yang2, Xian Yang2, Yaobing 4 Chen 5, Chang Shu2, Ziwei Fan2, Jiefeng Gan2, Xinyu Zou2, Renhao Huang2, Changzheng Zhang6, 5 Xiaowu Liu6, Dandan Tu6, Chuou Xu1, Wenqing Zhang2, Dehua Yang7, Ming-Wei Wang7, Xi Wang8, 6 Xiaoliang Xie8, Hongxiang Leng9, Nagaraj Holalkere10, Neil J. Halin10, Ihab Roushdy Kamel11, Jia Wu12, 7 Xuehua Peng13, Xiang Wang14, Jianbo Shao13, Pattanasak Mongkolwat15, Jianjun Zhang16,17, Daniel L. 8 Rubin18, Guoping Wang 5, Chuangsheng Zheng3*, Zhen Li1*,Xiang Bai2*, Tian Xia2,5* 9 1Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and 10 Technology, Wuhan 430030, China. 11 2School of Electronic Information and Communications, Huazhong University of Science and Technology, Wuhan 12 430074, China. 13 3Department of Radiology, Union Hospital of Tongji Medical College, Huazhong University of Science and 14 Technology, Wuhan 430022, China. 15 4Department of Information Management, Tongji Hospital, Huazhong University of Science and Technology, 16 Wuhan 430030, China. 17 5Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 18 Wuhan 430030, China. 19 6HUST-HW Joint Innovation Lab, Wuhan 430074, China.
    [Show full text]
  • Engineered Interferon Alpha Effectively Improves Clinical Outcomes of COVID-19 Patients
    Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients Chuan Li Department of Thoracic Surgery, West China Hospital, Sichuan University Fengming Luo Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Chengwu Liu Department of Thoracic Surgery, West China Hospital, Sichuan University Nian Xiong Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Zhihua Xu Department of Critical Care Medicine, Mianyang Central Hospital Wei Zhang Department of Respiratory and Critical Care Medicine, First aliated hospital, the Second Military Medical University Ming Yang Department of Respiratory Medicine, The Public Health Clinical Center of Chengdu Ye Wang Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Dan Liu Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Chao Yu Department of Respiratory and Critical Care Medicine, Naval Hospital of Eastern Theater of PLA Jia Zeng Department of Aviation Disease, Naval medical center of PLA, the Second Military Medical University Li Zhang Department of Respiratory Disease, Wuhan Red Cross Hospital Duo Li Department of Respiratory Disease, The Aliated Hospital of Southwest Medical University Yanbin Liu Center of Infectious Diseases, West China Hospital, Sichuan University Mei Feng Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Ruoyang Liu Page 1/21 Department
    [Show full text]
  • Abstract Submission/Modification Form
    Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study Yuqin Song, MD, PhD,1 Quanli Gao, MD,2 Huilai Zhang, PhD,3 Lei Fan, MD, PhD,4 Jianfeng Zhou, PhD,5 Dehui Zou, MD,6 Wei Li, MD,7 Haiyan Yang, PhD,8 Ting Liu, MD, PhD,9 Quanshun Wang, MD, PhD,10 Fangfang Lv, MD,11 Yu Yang, MD,12 Haiyi Guo, MD,13 Liudi Yang, MD,13 Rebecca Elstrom, 13 13 13 13 1 MD, Jane Huang, MD, William Novotny, MD, Vivian Wei, PhD, and Jun Zhu, MD, PhD 1Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China 2Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China 3Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, China 4Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China 5Department of Hematology, Tongji Hospital, Tongji Medical College, Wuhan, China 6State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China 7Department of Hematology, Cancer Center, The First Hospital of Jilin University, Changchun, China 8Department of Oncology, Zhejiang
    [Show full text]
  • Dosimetric and Biological Comparison of Treatment Plans Between LINAC and Robot Systems in Stereotactic Body Radiation Therapy for Localized Prostate Cancer
    Dosimetric and biological comparison of treatment plans between LINAC and robot systems in stereotactic body radiation therapy for localized prostate cancer Zhitao Dai National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Lian Zhu Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Tingting Cao ongji hospital, Tongji Medical college, Huazhong University of Science and Technology,Wuhan 430030, China. Aihua Wang Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Xueling Guo Department of Radiation Oncology, Changhai Hospital aliated to Navy Medical University, Shanghai, China. Yongming Liu Department of Radiation Oncology, Changhai Hospital aliated to Navy Medical University, Shanghai, China. Yayun Zhuang Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Peiying Yang Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Ning Li National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Huojun Zhang ( [email protected] ) Department of Radiation Oncology, Changhai Hospital aliated to Navy Medical University, Shanghai, China. Zuolin Xiang Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China.
    [Show full text]
  • UNITED STATES BANKRUPTCY COURT Southern District of New York *SUBJECT to GENERAL and SPECIFIC NOTES to THESE SCHEDULES* SUMMARY
    UNITED STATES BANKRUPTCY COURT Southern District of New York Refco Capital Markets, LTD Case Number: 05-60018 *SUBJECT TO GENERAL AND SPECIFIC NOTES TO THESE SCHEDULES* SUMMARY OF AMENDED SCHEDULES An asterisk (*) found in schedules herein indicates a change from the Debtor's original Schedules of Assets and Liabilities filed December 30, 2005. Any such change will also be indicated in the "Amended" column of the summary schedules with an "X". Indicate as to each schedule whether that schedule is attached and state the number of pages in each. Report the totals from Schedules A, B, C, D, E, F, I, and J in the boxes provided. Add the amounts from Schedules A and B to determine the total amount of the debtor's assets. Add the amounts from Schedules D, E, and F to determine the total amount of the debtor's liabilities. AMOUNTS SCHEDULED NAME OF SCHEDULE ATTACHED NO. OF SHEETS ASSETS LIABILITIES OTHER YES / NO A - REAL PROPERTY NO 0 $0 B - PERSONAL PROPERTY YES 30 $6,002,376,477 C - PROPERTY CLAIMED AS EXEMPT NO 0 D - CREDITORS HOLDING SECURED CLAIMS YES 2 $79,537,542 E - CREDITORS HOLDING UNSECURED YES 2 $0 PRIORITY CLAIMS F - CREDITORS HOLDING UNSECURED NON- YES 356 $5,366,962,476 PRIORITY CLAIMS G - EXECUTORY CONTRACTS AND UNEXPIRED YES 2 LEASES H - CODEBTORS YES 1 I - CURRENT INCOME OF INDIVIDUAL NO 0 N/A DEBTOR(S) J - CURRENT EXPENDITURES OF INDIVIDUAL NO 0 N/A DEBTOR(S) Total number of sheets of all Schedules 393 Total Assets > $6,002,376,477 $5,446,500,018 Total Liabilities > UNITED STATES BANKRUPTCY COURT Southern District of New York Refco Capital Markets, LTD Case Number: 05-60018 GENERAL NOTES PERTAINING TO SCHEDULES AND STATEMENTS FOR ALL DEBTORS On October 17, 2005 (the “Petition Date”), Refco Inc.
    [Show full text]
  • VTC2018-Fall Final Program
    The 88th IEEE Vehicular Technology Conference Final Programme 27 – 30 August 2018 Chicago, USA Welcome from the General Chair I am extremely pleased to have the honor of welcoming Skyscrapers and Modern “Glass and Steel” you to the 88th IEEE Vehicular Technology Architecture, nuclear energy, and of course two-way Conference, VTC2018-Fall, and to its host city, the radios and the cellphone. Greater Chicago is home to a great International City of Chicago. very vibrant academic environment with nearly 100 Beyond the slate of outstanding tutorials, workshops, colleges and universities. and technical sessions, VTC2018-Fall will feature I’d like to take this opportunity to thank all the members world-class keynote speakers, exciting plenary panels, of the Organizing Committee and Technical Program and a three-day Industry Program. Marty Cooper, Committee and their leaders for the outstanding work Honorary Conference Chair, a native Chicagoan, and they have done to create this incredible event. I am among other contribution, the “Father of the Cellphone” literally amazed by the dedication and diligence of the will provide our lead-off keynote. The four-day hundreds of experts in our research community who program features Tutorials, Workshops and a mini- have devoted their time to paper review process. Finally Conference on Monday followed by Theme Days I would like to recognize the excellence and the focusing on 5G and Applications, Autonomous tremendous research and preparation shown by the Vehicles, and Smart Cities and IoT. Attendees will numerous authors who submitted their works for have the opportunity to hear from some of the world’s consideration and especially those involve with the most distinguished industry leaders and researchers.
    [Show full text]